前往化源商城

Molecular Pharmacology 2015-02-01

An integrated biological approach to guide the development of metal-chelating inhibitors of influenza virus PA endonuclease.

Annelies Stevaert, Salvatore Nurra, Nicolino Pala, Mauro Carcelli, Dominga Rogolino, Caitlin Shepard, Robert A Domaoal, Baek Kim, Mercedes Alfonso-Prieto, Salvatore A E Marras, Mario Sechi, Lieve Naesens

文献索引:Mol. Pharmacol. 87(2) , 323-37, (2015)

全文:HTML全文

摘要

The influenza virus PA endonuclease, which cleaves capped cellular pre-mRNAs to prime viral mRNA synthesis, is a promising target for novel anti-influenza virus therapeutics. The catalytic center of this enzyme resides in the N-terminal part of PA (PA-Nter) and contains two (or possibly one or three) Mg(2+) or Mn(2+) ions, which are critical for its catalytic function. There is great interest in PA inhibitors that are optimally designed to occupy the active site and chelate the metal ions. We focused here on a series of β-diketo acid (DKA) and DKA-bioisosteric compounds containing different scaffolds, and determined their structure-activity relationship in an enzymatic assay with PA-Nter, in order to build a three-dimensional pharmacophore model. In addition, we developed a molecular beacon (MB)-based PA-Nter assay that enabled us to compare the inhibition of Mn(2+) versus Mg(2+), the latter probably being the biologically relevant cofactor. This real-time MB assay allowed us to measure the enzyme kinetics of PA-Nter or perform high-throughput screening. Several DKA derivatives were found to cause strong inhibition of PA-Nter, with IC50 values comparable to that of the prototype L-742,001 (i.e., below 2 μM). Among the different compounds tested, L-742,001 appeared unique in having equal activity against either Mg(2+) or Mn(2+). Three compounds ( 10: , with a pyrrole scaffold, and 40: and 41: , with an indole scaffold) exhibited moderate antiviral activity in cell culture (EC99 values 64-95 μM) and were proven to affect viral RNA synthesis. Our approach of integrating complementary enzymatic, cellular, and mechanistic assays should guide ongoing development of improved influenza virus PA inhibitors. Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

相关化合物

结构式 名称/CAS号 全部文献
甘油 结构式 甘油
CAS:56-81-5
氯化钠 结构式 氯化钠
CAS:7647-14-5
L-谷氨酰胺 结构式 L-谷氨酰胺
CAS:56-85-9
碳酸氢钠 结构式 碳酸氢钠
CAS:144-55-8
氯化钠-35cl 结构式 氯化钠-35cl
CAS:20510-55-8
次氮基三乙酸钠盐 结构式 次氮基三乙酸钠盐
CAS:5064-31-3
磷酸氯喹 结构式 磷酸氯喹
CAS:50-63-5
次氮基三乙酸二钠盐 结构式 次氮基三乙酸二钠盐
CAS:15467-20-6
利巴韦林 结构式 利巴韦林
CAS:36791-04-5